Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Polyethylene glycol + senna is a combination of two laxatives used primarily for bowel preparation before colonoscopy and for the treatment of constipation. Polyethylene glycol (PEG) acts as an osmotic laxative, retaining water in the stool to soften it and increase stool frequency. Senna is a stimulant laxative that contains sennosides, which irritate the lining of the bowel to stimulate intestinal motility and promote defecation. The combination aims to improve patient tolerance by reducing PEG volume while maintaining effective bowel cleansing, with studies showing non-inferior efficacy compared to high-volume PEG regimens but with fewer side effects such as nausea and bloating[3][5]. Both agents are approved for over-the-counter use individually; their combination is commonly used in clinical practice for colonoscopy preparation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on polyethylene glycol + senna.